Treatment outcomes among childhood extensively drug-resistant tuberculosis patients in Pakistan

Muhammad Abubakar; Nafees Ahmad; Muhammad Atif; Amer Hayat Khan; Abdul Ghafoor

doi:10.1183/23120541.00551-2021

Tables

TABLE 1

Distribution of treatment outcome among childhood extensively drug-resistant tuberculosis patients (N=42)

Characteristics	Treatment outcome		p-value
Characteristics	Successful	Unsuccessful	p-value
Age			0.537
<10 years	9 (45%)	11 (55%)
10–14 years	12 (54.5%)	10 (45.5%)
Baseline weight			0.525
≤35 kg	7 (43.8%)	9 (56.2%)
>35 kg	14 (53.8%)	12 (46.2%)
Sex			0.495
Female	14 (46.7%)	16 (53.3%)
Male	7 (58.3%)	5 (41.7%)
History of TB treatment			0.726
No	5 (45.5%)	6 (54.5%)
Yes	16 (51.6%)	15 (48.4%)
History of use of SLD			0.095
No	17 (58.6%)	12 (41.4%)
Yes	4 (30.8%)	9 (69.2%)
History of MDR-TB treatment			0.079
No	18 (58.1%)	13 (41.9%)
Yes	3 (27.3%)	8 (72.7%)
Comorbidities			1.000
No	21 (52.5%)	19 (47.5%)
Yes	0 (0.0%)	2 (100%)
Baseline sputum smear grading			Not measured
Negative	3 (37.5%)	5 (62.5%)
Scanty^#	1 (100%)	0 (0.0%)
+1^¶	11 (64.7%)	6 (35.3%)
+2⁺	1 (16.7%)	5 (83.3%)
+3^§	5 (50%)	5 (50%)
Sputum culture conversion			0.976
<2 months	13 (72.2%)	5 (27.8%)
>2 months	8 (72.7%)	3 (27.3%)
Use of linezolid			0.726
No	5 (45.5%)	6 (54.6%)
Yes	16 (51.6%)	15 (48.4%)
Use of clofazimine			0.064
No	14 (63.6%)	8 (36.4%)
Yes	7 (35%)	13 (65%)
Use of bedaquiline			0.634
No	18 (48.6%)	19 (51.4%)
Yes	3 (60%)	2 (40%)

TB: tuberculosis; SLD: second-line drug; MDR: multidrug-resistant. ^#: 1–9 acid-fast bacilli (AFB) per 100 high-power fields (HPFs); ^¶: 10–99 AFB per 100 HPFs; ⁺: 1–9 AFB per HPF; ^§: >9 AFB per HPF.